Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.76
(-1.43%)
CAD 2.76
(-1.43%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 19.27 Million USD | 27.61% |
| 2022 | 14.64 Million USD | 333.83% |
| 2021 | 15.16 Million USD | -192.83% |
| 2020 | -23.6 Million USD | 293.35% |
| 2019 | 7.03 Million CAD | 20.64% |
| 2018 | 159 Thousand CAD | 171.24% |
| 2017 | -2.06 Million CAD | 28.82% |
| 2016 | -697.72 Thousand CAD | 15.07% |
| 2015 | -1.15 Million CAD | -180.04% |
| 2014 | -3.85 Million CAD | 75.97% |
| 2013 | -4.88 Million CAD | -3164.06% |
| 2012 | -2.02 Million CAD | -109759.78% |
| 2011 | -136.14 CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 5.74 Million USD | -0.12% |
| 2023 Q4 | 4.27 Million USD | 41.71% |
| 2023 Q3 | 3.01 Million USD | -39.88% |
| 2023 Q2 | 5.01 Million USD | -20.19% |
| 2023 Q1 | 6.28 Million USD | 45.71% |
| 2023 FY | - USD | 27.61% |
| 2022 Q1 | 1.57 Million USD | 93.01% |
| 2022 Q2 | 3.86 Million USD | 145.46% |
| 2022 Q3 | 4.78 Million USD | 23.82% |
| 2022 Q4 | 4.31 Million USD | -9.88% |
| 2022 FY | - USD | 333.83% |
| 2021 FY | - USD | -192.83% |
| 2021 Q2 | -2.65 Million USD | 52.39% |
| 2021 Q3 | 1.19 Million USD | 144.92% |
| 2021 Q1 | -5.58 Million USD | -126.93% |
| 2021 Q4 | 816 Thousand USD | -31.66% |
| 2020 Q3 | 3.56 Million CAD | 83.24% |
| 2020 Q4 | -2.46 Million USD | -169.07% |
| 2020 Q2 | 1.94 Million CAD | -41.68% |
| 2020 Q1 | 3.33 Million CAD | 156.55% |
| 2020 FY | - USD | 293.35% |
| 2019 Q1 | 54.25 Thousand CAD | 117.38% |
| 2019 Q3 | 307.74 Thousand CAD | 590.51% |
| 2019 Q2 | 44.56 Thousand CAD | -17.86% |
| 2019 FY | - CAD | 20.64% |
| 2019 Q4 | 1.29 Million CAD | 322.14% |
| 2018 Q1 | -247.79 Thousand CAD | 53.99% |
| 2018 Q4 | -312.18 Thousand CAD | -118.54% |
| 2018 FY | - CAD | 171.24% |
| 2018 Q3 | 1.68 Million CAD | 164.39% |
| 2018 Q2 | -2.61 Million CAD | -955.1% |
| 2017 Q1 | -646.84 Thousand CAD | 32.86% |
| 2017 Q3 | -609.45 Thousand CAD | -463.28% |
| 2017 Q4 | -538.55 Thousand CAD | 11.63% |
| 2017 FY | - CAD | 28.82% |
| 2017 Q2 | -108.19 Thousand CAD | 83.27% |
| 2016 Q2 | -464.58 Thousand CAD | 85.87% |
| 2016 FY | - CAD | 15.07% |
| 2016 Q1 | -3.28 Million CAD | -195.68% |
| 2016 Q4 | -963.39 Thousand CAD | -51.95% |
| 2016 Q3 | -634 Thousand CAD | -36.47% |
| 2015 FY | - CAD | -180.04% |
| 2015 Q4 | -1.11 Million CAD | -77.44% |
| 2015 Q3 | -626.86 Thousand CAD | -11.22% |
| 2015 Q2 | -563.6 Thousand CAD | 49.59% |
| 2015 Q1 | -1.11 Million CAD | -176.53% |
| 2014 Q1 | -738.71 Thousand CAD | 0.0% |
| 2014 FY | - CAD | 75.97% |
| 2014 Q4 | 1.46 Million CAD | 255.51% |
| 2014 Q2 | -1.03 Million CAD | -39.88% |
| 2014 Q3 | -939.44 Thousand CAD | 9.08% |
| 2013 Q3 | -56.15 Thousand CAD | -240.82% |
| 2013 FY | - CAD | -3164.06% |
| 2013 Q1 | -1995.89 CAD | 79.78% |
| 2013 Q2 | -16.47 Thousand CAD | -725.48% |
| 2012 Q4 | -9870.76 CAD | 98.19% |
| 2012 Q1 | -29.75 Thousand CAD | 68.51% |
| 2012 Q3 | -545.71 Thousand CAD | -22794.99% |
| 2012 FY | - CAD | -109759.78% |
| 2012 Q2 | -2383.54 CAD | 91.99% |
| 2011 Q4 | -94.47 Thousand CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aurora Cannabis Inc. | 20.47 Million CAD | 5.851% |
| Avicanna Inc. | -7.35 Million CAD | 362.064% |
| Avant Brands Inc. | 4.83 Million CAD | -298.594% |
| Cardiol Therapeutics Inc. | -27.87 Million CAD | 169.139% |
| Crescita Therapeutics Inc. | 45 Thousand CAD | -42735.556% |
| Knight Therapeutics Inc. | 40.89 Million CAD | 52.867% |
| MediPharm Labs Corp. | -10.47 Million CAD | 283.966% |
| OrganiGram Holdings Inc. | -207.61 Million CAD | 109.284% |
| Canopy Growth Corporation | -312.82 Million CAD | 106.162% |
| Willow Biosciences Inc. | -11.06 Million CAD | 274.27% |
| Auxly Cannabis Group Inc. | -10.82 Million CAD | 278.069% |